Variations in survival and perioperative complications between hospitals based on data from two phase III clinical trials for oesophageal cancer
Open Access
- 11 June 2015
- journal article
- research article
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 102 (9) , 1088-1096
Abstract
Background: Variations in institutional practice may contribute to different outcomes of cancer treatment. The impact of interinstitutional heterogeneity on outcomes between hospitals after oesophagectomy has not been examined previously using data from surgical clinical trials. Methods: The data from two phase III trials for oesophageal cancer were used. Japan Clinical Oncology Group (JCOG) 9204 involved oesophagectomy (92-OP) versus oesophagectomy plus postoperative chemotherapy (92-POST), with accrual from 1992 to 1997. JCOG9907 involved postoperative chemotherapy (99-POST) versus preoperative chemotherapy (99-PRE), with accrual from 2000 to 2006. Hospitals contributing fewer than three patients were excluded. The influence of time and preoperative chemotherapy on interinstitutional heterogeneity related to postoperative complications and 5-year overall survival were evaluated by comparisons within and between these trial groups. Heterogeneity was estimated by a mixed-effects model after adjusting for age, sex, performance status, location of the primary tumour and clinical stage. Results: Twelve hospitals in 92-OP (114 patients), 13 in 92-POST (114), 19 in 99-POST (158) and 18 in 99-PRE (154) were eligible. There was considerable heterogeneity in predicted postoperative complications in both groups in JCOG9204 (median 31·3 (range 15·0–68·2) per cent), and in 99-PRE (35·2 (22·6–46·6) per cent) but not in 99-POST (27·7 (27·7–27·7) per cent) from JCOG9907. A similar pattern was seen for predicted overall survival (92-POST: 66·4 (range 64·1–68·9) per cent; 99-PRE: 55·9 (54·0–59·7) per cent; 99-POST: 44·4 (44·4–44·4) per cent). Conclusion: Interinstitutional heterogeneity regarding complications and survival after oesophagectomy is a problem that merits wider consideration.Keywords
Funding Information
- National Cancer Center Research and Development Funds from the Ministry of Health, Labour and Welfare of Japan (23-A-16, 26-A-4)
This publication has 20 references indexed in Scilit:
- Hospital and Surgeon Volume in Relation to Survival After Esophageal Cancer Surgery in a Population-Based StudyJournal of Clinical Oncology, 2013
- Trends in Hospital Volume and Operative Mortality for High-Risk SurgeryNew England Journal of Medicine, 2011
- Esophagectomy for cancer: clinical concerns support centralizing operations within the larger hospitalsDiseases of the Esophagus, 2010
- The Effect of Provider Case Volume on Cancer Mortality: Systematic Review and Meta-AnalysisCA: A Cancer Journal for Clinicians, 2009
- Centralization of Esophageal Cancer Surgery: Does It Improve Clinical Outcome?Annals of Surgical Oncology, 2009
- Volume-Based Referral for Cancer Surgery: Informing the DebateJournal of Clinical Oncology, 2007
- Centralisation of Oesophagogastric Cancer Services: Can Specialist Units Deliver?The Annals of The Royal College of Surgeons of England, 2006
- Surgeon Volume and Operative Mortality in the United StatesNew England Journal of Medicine, 2003
- Mortality and morbidity in gastro-oesophageal cancer surgery: initial results of ASCOT multicentre prospective cohort studyBMJ, 2003
- Cohort study in South and West England of the influence of specialization on the management and outcome of patients with oesophageal and gastric cancersBritish Journal of Surgery, 2002